Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2013

Nov 4, 2013

31565_dirs_2013-11-04_07c5100f-2bf8-4ebe-a674-96b2ebe522b8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2013-11-01

Reporting Person: CONCANNON BRIAN (Director, President & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-11-01 Common Stock M 4600.0 $25.535 Acquired 134907 Direct
2013-11-01 Common Stock S 4600.0 $39.9578 Disposed 130307 Direct
2013-11-01 Common Stock M 3000.0 $13.0525 Acquired 133307 Direct
2013-11-01 Common Stock S 3000.0 $39.9604 Disposed 130307 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-11-01 Non-Qualified Stock Option (right to buy) $13.0525 M 3000.0 Disposed 2014-05-05 Common Stock (3000) Direct
2013-11-01 Non-Qualified Stock Option (right to buy) $25.535 M 4600.0 Disposed 2014-10-24 Common Stock (4600) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Non-Qualified Stock Option (right to buy) $26.47 2016-10-27 Common Stock (159350) 159350 Direct
Non-Qualified Stock Option (right to buy) $27.275 2015-10-22 Common Stock (57176) 57176 Direct
Non-Qualified Stock Option (right to buy) $27.495 2017-10-27 Common Stock (236750) 236750 Direct
Non-Qualified Stock Option (right to buy) $27.685 2016-04-02 Common Stock (65690) 65690 Direct
Non-Qualified Stock Option (right to buy) $30.67 2018-10-25 Common Stock (219572) 219572 Direct
Non-Qualified Stock Option (right to buy) $39.055 2019-10-24 Common Stock (250382) 250382 Direct
Non-Qualified Stock Option (right to buy) $41.66 2019-10-23 Common Stock (234899) 234899 Direct
Performance Shares $0.0 2017-12-31 Common Stock (50000) 50000 Direct

Footnotes

F1: Pursuant to a 10b5-1 Plan.

F2: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

F3: Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).